HomeOrtho Regenerative Technologies Inc

Ortho Regenerative Technologies Inc

Ortho Regenerative Technologies Receives Clinical Hold Letter From the U.S. FDA

The FDA has requested additional Chemistry, Manufacturing, and Control ("CMC") related information. The Company is confident in its ability to address and provide the FDA with the required information and testing data over the coming four to six weeks.

Ortho-R Receives FDA Regulatory Designation and Jurisdictional Assignment

Ortho-R is designated as a Drug/Biologic combination product, by the FDA Office for Combination Products. The jurisdictional assignment for Ortho-R will be the Center for Biologics Evaluation and Research (CBER). The news was announced today by Ortho...

Ortho RTi Confirms Timeline to Initiate Human Clinical Program After Meeting with the FDA

As a result, the Company is in the position to submit its Investigational New Drug while completing its pivotal study and confirms the timeline to initiate human clinical program by year end.

Ortho RTi Announces Results of Two Key Scientific Studies

2/4/19: Both key scientific studies validate its product's ability to improve the repair of two distinct joint tissues, the rotator cuff tendon and articular cartilage.

Data from Ortho-R Pilot Study in Rotator Cuff Repair is Compelling

4/2/18: Conducted by researchers from Montreal's prestigious École Polytechnique, the pilot dose escalation study used MR imaging outcomes, read by two blinded experts at 3 intervals, to compare the results of Ortho-R versus standard of care in a non-clinical rotator cuff injury model in sheep.